Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients (MMRinOLT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01770119|
Recruitment Status : Recruiting
First Posted : January 17, 2013
Last Update Posted : September 18, 2020
Measles is a vaccine-preventable disease, which can be life-threatening in immunosuppressed children. Currently, measles vaccine is not recommended in pediatric orthotopic liver transplant recipients, because it is a live-attenuated vaccine.
We want to assess the influence of immunosuppression on immunity against measles in previously vaccinated children and to evaluate the induction of B cell and T cell response against measles elicited by vaccination in children at least 12 months after transplantation.
|Condition or disease||Intervention/treatment||Phase|
|Measles||Biological: MMR vaccination||Phase 4|
Eligible children in Group 2 will receive a standard dose (0.5 ml) of MMR vaccine during the first medical visit (V1). The lot number and the expiration date will both be recorded on the patient's case report form (CRF). A serological evaluation 4-8 weeks after MMR will identify children requiring an additional dose given 1-2 months apart, as currently recommended for subjects 1 year-old or with limited immune competence (i.e. HIV-infected children). Serological evaluation 4-8 weeks after the second dose or at the one-year follow-up will identify eventual non-responder requiring a third dose. Three will be the maximal number of administrated dose according to this protocol. The persistence of measles-specific antibodies will be assessed yearly, when patients come for their routine visit to the transplant center.
Children who do not need MMR immunization because of protective levels will be monitored yearly for maintenance of antibody levels during routine yearly visits/ blood samplings and will not have further intervention.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||October 2025|
Experimental: MMR vaccination
MMR vaccine to seronegative pediatric SOT recipients
Biological: MMR vaccination
Unprotected children will be vaccinated with two MMR vaccines
- serologic response to MMR vaccine in seronegative transplant recipients [ Time Frame: 2 months after vaccination ]Pediatric transplant recipients will be vaccinated with MMR vaccine (previously seronegative) and their seroresponse will be measured 2 months later
- Persistance of seroresponse to MMR vaccine [ Time Frame: 3 years ]Seroresponse to MMR vaccine will be followed over time in pediatric transplant recipients
- Efficacy of MMR vaccine in pediatric SOT recipients [ Time Frame: 3 years ]Protection against vaccine-preventable diseases will be assessed in pediatric SOT recipients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770119
|Children's Hospital of Geneva||Recruiting|
|Geneva, GE, Switzerland, 1211|
|Contact: Klara M Posfay-Barbe, MD, MS +41223725462 Klara.PosfayBarbe@hcuge.ch|
|Contact: Natasha Loevy, MD +41223725481 Natasha.Loevy@hcuge.ch|
|Principal Investigator: Klara M Posfay-Barbe, MD, MS|
|Principal Investigator:||Klara M Posfay-Barbe, MD, MS||University Hospitals of Geneva|